Altered phosphorylation but no neurodegeneration in a mouse model of tau hyperphosphorylation

Neurobiology of Aging

Volumn 32, Issue 6, 2011, Pages 991-1006

  Hundelt, M ^a   Fath, T ^b,f   Selle, K ^a   Oesterwind, K ^a   Jordan, J ^a   Schultz, C ^c   Gotz J ^d   von Engelhardt, J ^e   Monyer, H ^e   Lewejohann, L ^f   Sachser, N ^f   Bakota, L ^a   Brandt, R ^a  

^a UNIVERSITY OF OSNABRÜCK   (Germany)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Degeneration; Pseudohyperphosphorylation; Tau protein; Tauopathy; Transgenic mouse

Indexed keywords

CASPASE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; FOREBRAIN; LEARNING; MALE; MEMORY; MOUSE; NEOCORTEX; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; WILD TYPE;

AGE FACTORS; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MINISATELLITE REPEATS; NERVE DEGENERATION; NEURONS; PHOSPHORYLATION; PROSENCEPHALON; PROTEIN BINDING; SILVER STAINING; SULFATE ADENYLYLTRANSFERASE; TAU PROTEINS;

EID: 79955976354     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.06.007     Document Type: Article

References (67)

1. Allen B., Ingram E., Takao M., Smith M.J., Jakes R., Virdee K., Yoshida H., Holzer M., Craxton M., Emson P.C., Atzori C., Migheli A., Crowther R.A., Ghetti B., Spillantini M.G., Goedert M. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 2002, 22:9340-9351.
2. Alonso A.C., Grundke-Iqbal I., Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med. 1996, 2:783-787.
3. Alonso A.C., Zaidi T., Grundke-Iqbal I., Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:5562-5566.
4. Andorfer C., Kress Y., Espinoza M., de Silva R., Tucker K.L., Barde Y.A., Duff K., Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 2003, 86:582-590.
5. Arendt T. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization. Neuroscience 2001, 102:723-765.
6. Barnes C.A. Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J. Comp. Physiol. Psychol. 1979, 93:74-104.
7. Binder L.I., Frankfurter A., Rebhun L.I. The distribution of tau in the mammalian central nervous system. J. Cell Biol. 1985, 101:1371-1378.
8. Braak E., Braak H., Mandelkow E.M. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. (Berl.) 1994, 87:554-567.
9. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 1991, 82:239-259.
10. Brandt R., Gergou A., Wacker I., Fath T., Hutter H. A Caenorhabditis elegans model of tau hyperphosphorylation: Induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau. Neurobiol. Aging 2009, 30:22-33.
11. Bubenaite J. Über einige Erfahrungen mit der Golgi-Methode. Z. Wiss. Mikr. 1929, 46:359-360.
12. Canudes A.M., Gutierrez-Cuesta J., Rodriguez M.I., Acuna-Castroviejo D., Sureda F.X., Camins A., Pallas M. Hyperphosphorylation of microtubule-associated protein tau in senescence-accelerated mouse (SAM). Mech. Ageing Dev. 2005, 126:1300-1304.
13. Chen F., David D., Ferrari A., Götz J. Posttranslational modifications of tau - role in human tauopathies and modeling in transgenic animals. Curr. Drug Targets 2004, 5:503-515.
14. David D.C., Hauptmann S., Scherping I., Schuessel K., Keil U., Rizzu P., Ravid R., Drose S., Brandt U., Muller W.E., Eckert A., Gotz J. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem. 2005, 280:23802-23814.
15. DeTure M., Ko L.W., Easson C., Yen S.H. Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau. Am. J. Pathol. 2002, 161:1711-1722.
16. Development Core Team R A Language and Environment for Statistical Computing 2005, R Foundation for Statistical Computing, Vienna.
17. Double K.L., Halliday G.M., Kril J.J., Harasty J.A., Cullen K., Brooks W.S., Creasey H., Broe G.A. Topography of brain atrophy during normal aging and Alzheimer's disease. Neurobiol. Aging 1996, 17:513-521.
18. Efron B. Bootstrap methods: another look at the jackknife. Ann. Stat. 1979, 7:1-26.
19. Eidenmüller J., Fath T., Hellwig A., Reed J., Sontag E., Brandt R. Structural and functional implications of tau hyperphosphorylation: information from phosphorylation-mimicking mutated tau proteins. Biochemistry 2000, 39:13166-13175.
20. Eidenmüller J., Fath T., Maas T., Pool M., Sontag E., Brandt R. Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. Biochem. J. 2001, 357:759-767.
21. Fath T., Eidenmüller J., Brandt R. Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease. J. Neurosci. 2002, 22:9733-9741.
22. Fox W.M. Reflex-ontogeny and behavioural development of the mouse. Anim. Behav. 1965, 13:234-241.
23. Gallyas F. Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol. Acad. Sci. Hung. 1971, 19:1-8.
24. Games D., Buttini M., Kobayashi D., Schenk D., Seubert P. Mice as models: transgenic approaches and Alzheimer's disease. J. Alzheimers Dis. 2006, 9:133-149.
25. Goedert M., Jakes R., Vanmechelen E. Monoclonal antibody AT8 recognizes tau protein phosphorylated at both serine 202 and threonine 205. Neurosci. Lett. 1995, 189:167-169.
26. Gomez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 1997, 41:17-24.
27. Götz J., Probst A., Spillantini M.G., Schafer T., Jakes R., Burki K., Goedert M. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 1995, 14:1304-1313.
28. Götz J., Streffer J.R., David D., Schild A., Hoerndli F., Pennanen L., Kurosinski P., Chen F. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol. Psychiatry 2004, 9:664-683.
29. Hanger D.P., Betts J.C., Loviny T.L., Blackstock W.P., Anderton B.H. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 1998, 71:2465-2476.
30. Hanger D.P., Byers H.L., Wray S., Leung K.Y., Saxton M.J., Seereeram A., Reynolds C.H., Ward M.A., Anderton B.H. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J. Biol. Chem. 2007, 282:23645-23654.
31. Holtmaat A.J., Trachtenberg J.T., Wilbrecht L., Shepherd G.M., Zhang X., Knott G.W., Svoboda K. Transient and persistent dendritic spines in the neocortex in vivo. Neuron 2005, 45:279-291.
32. Holzer M., Holzapfel H.P., Zedlick D., Bruckner M.K., Arendt T. Abnormally phosphorylated tau protein in Alzheimer's disease: heterogeneity of individual regional distribution and relationship to clinical severity. Neuroscience 1994, 63:499-516.
33. Jacobsen J.S., Wu C.C., Redwine J.M., Comery T.A., Arias R., Bowlby M., Martone R., Morrison J.H., Pangalos M.N., Reinhart P.H., Bloom F.E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:5161-5166.
34. Lassmann H., Bancher C., Breitschopf H., Wegiel J., Bobinski M., Jellinger K., Wisniewski H.M. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol. (Berl.) 1995, 89:35-41.
35. Lee V.M., Kenyon T.K., Trojanowski J.Q. Transgenic animal models of tauopathies. Biochim. Biophys. Acta 2005, 1739:251-259.
36. Leschik J., Welzel A., Weissmann C., Eckert A., Brandt R. Inverse and distinct modulation of tau-dependent neurodegeneration by presenilin 1 and amyloid-beta in cultured cortical neurons: evidence that tau phosphorylation is the limiting factor in amyloid-beta-induced cell death. J. Neurochem. 2007, 101:1303-1315.
37. Leuba G., Kraftsik R. Visual cortex in Alzheimer's disease: occurrence of neuronal death and glial proliferation, and correlation with pathological hallmarks. Neurobiol. Aging 1994, 15:29-43.
38. Lewejohann L., Skryabin B.V., Sachser N., Prehn C., Heiduschka P., Thanos S., Jordan U., Dell'Omo G., Vyssotski A.L., Pleskacheva M.G., Lipp H.P., Tiedge H., Brosius J., Prior H. Role of a neuronal small non-messenger RNA: behavioural alterations in BC1 RNA-deleted mice. Behav. Brain Res. 2004, 154:273-289.
39. Maas T., Eidenmuller J., Brandt R. Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J. Biol. Chem. 2000, 275:15733-15740.
40. Mayford M., Wang J., Kandel E.R., O'Dell T.J. CaMKII regulates the frequency-response function of hippocampal synapses for the production of both LTD and LTP. Cell 1995, 81:891-904.
41. McGowan E., Eriksen J., Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 2006, 22:281-289.
42. Merrick S.E., Demoise D.C., Lee V.M. Site-specific dephosphorylation of tau protein at Ser202/Thr205 in response to microtubule depolymerization in cultured human neurons involves protein phosphatase 2A. J. Biol. Chem. 1996, 271:5589-5594.
43. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Titani K., Ihara Y. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 1995, 270:823-829.
44. Patrick G.N., Zukerberg L., Nikoloc M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402:615-622.
45. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, New York. Second Edition.
46. Peters A., Morrison J.H., Rosene D.L., Hyman B.T. Are neurons lost from the primate cerebral cortex during normal aging?. Cereb. Cortex 1998, 8:295-300.
47. Plattner F., Angelo M., Giese K.P. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 2006, 281:25457-25465.
48. Poeggel G., Helmeke C., Abraham A., Schwabe T., Friedrich P., Braun K. Juvenile emotional experience alters synaptic composition in the rodent cortex, hippocampus, and lateral amygdala. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:16137-16142.
49. Porzig R., Singer D., Hoffmann R. Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein. Biochem. Biophys. Res. Commun. 2007, 358:644-649.
50. Prior H., Sachser N. Effects of enriched housing environment on the behaviour of young male and female mice in four exploratory tasks. J. Exp. Anim. Sci. 1995, 37:57-68.
51. Rogers D.C., Peters J., Martin J.E., Ball S., Nicholson S.J., Witherden A.S., Hafezparast M., Latcham J., Robinson T.L., Quilter C.A., Fisher E.M. SHIRPA, a protocol for behavioral assessment: validation for longitudinal study of neurological dysfunction in mice. Neurosci. Lett. 2001, 306:89-92.
52. Scheff S.W., Price D.A., Schmitt F.A., DeKosky S.T., Mufson E.J. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007, 68:1501-1508.
53. Schneider A., Biernat J., von Bergen M., Mandelkow E., Mandelkow E.M. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 1999, 38:3549-3558.
54. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
55. Shahani N., Subramaniam S., Wolf T., Tackenberg C., Brandt R. Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices. J. Neurosci. 2006, 26:6103-6114.
56. Siegel S. Non-parametric Statistics for the Behavioral Sciences 1956, McGraw Hill, New York.
57. Smale G., Nichols N.R., Brady D.R., Finch C.E., Horton W.E. Evidence for apoptotic cell death in Alzheimer's disease. Exp. Neurol. 1995, 133:225-230.
58. Sontag E., Nunbhakdi-Craig V., Lee G., Bloom G.S., Mumby M.C. Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron 1996, 17:1201-1207.
59. Spires T.L., Hyman B.T. Neuronal structure is altered by amyloid plaques. Rev. Neurosci. 2004, 15:267-278.
60. Spittaels K., Van den Haute C., Van Dorpe J., Bruynseels K., Vandezande K., Laenen I., Geerts H., Mercken M., Sciot R., Van Lommel A., Loos R., Van Leuven F. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am. J. Pathol. 1999, 155:2153-2165.
61. Spittaels K., Van den Haute C., Van Dorpe J., Geerts H., Mercken M., Bruynseels K., Lasrado R., Vandezande K., Laenen I., Boon T., Van Lint J., Vandenheede J., Moechars D., Loos R., Van Leuven F. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem. 2000, 275:41340-41349.
62. Su J.H., Anderson A.J., Cummings B.J., Cotman C.W. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport 1994, 5:2529-2533.
63. Tatebayashi Y., Miyasaka T., Chui D.H., Akagi T., Mishima K., Iwasaki K., Fujiwara M., Tanemura K., Murayama M., Ishiguro K., Planel E., Sato S., Hashikawa T., Takashima A. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13896-13901.
64. Vallee R.B. A taxol-dependent procedure for the isolation of microtubules and microtubule-associated proteins (MAPs). J. Cell Biol. 1982, 92:435-442.
65. Walsh R.N., Cummins R.A. The open-field test: a critical review. Psychol. Bull. 1976, 83:482-504.
66. Zhukareva V., Trojanowski J.Q., Lee V.M. Assessment of pathological tau proteins in frontotemporal dementias: qualitative and quantitative approaches. Am. J. Geriatr. Psychiatry 2004, 12:136-145.
67. Zhukareva V., Shah K., Uryu K., Braak H., Del Tredici K., Sundarraj S., Clark C., Trojanowski J.Q., Lee V.M. Biochemical analysis of tau proteins in argyrophilic grain disease, Alzheimer's disease, and Pick's disease: a comparative study. Am. J. Pathol. 2002, 161:1135-1141.